Diane E. Sullivan - 03 Jun 2025 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
03 Jun 2025, 16:24:21 UTC
Prior SEC filing
13 May 2025
Next SEC filing
21 Apr 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Diane E. Sullivan
Filing notes and source

Key filing fact

Diane E. Sullivan filed Form 4 for LEXICON PHARMACEUTICALS, INC. (LXRX) on 03 Jun 2025.

Key facts

  • This page summarizes Diane E. Sullivan's Form 4 filing for LEXICON PHARMACEUTICALS, INC. (LXRX).
  • 2 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 03 Jun 2025, 16:24.

Change

  • Previous filing in this sequence was filed on 13 May 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001968736 Primary reporting owner

Sullivan Diane E.

Relationship
Director
Address
2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS
Signature
/s/ Diane E. Sullivan
Signature date
03 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LXRX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
$0
Shares
+103,806
Change %
Price
$0.000000
Shares after
103,806
Date
03 Jun 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
103,806
Exercise price
$0.6216
Footnotes
F1
LXRX transaction Derivative

Restricted Stock Units

Award

Transaction value
$0
Shares
+89,312
Change %
Price
$0.000000
Shares after
89,312
Date
03 Jun 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
89,312
Exercise price
$0.000000
Footnotes
F2, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date.

Footnote F2

Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date.

Footnote F3

Each restricted stock unit represents a contingent right to receive one share of common stock.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .